Roche is committing $50 billion while Regeneron inked a $3 billion manufacturing deal with Fujifilm, allowing the pharma to ...

Gut Microbiota in Immuno-Oncology: A Practical Guide for Medical Oncologists With a Focus on Antibiotics Stewardship Bispecific antibodies (bsAbs) have emerged as a novel class of therapeutics, ...

Investors in Regeneron Pharmaceuticals, Inc. (Symbol: REGN) saw new options become available today, for the May 30th expiration. At Stock Options Channel, our YieldBoost formula has looked up and ...

ADAR1 Capital Management LLC dramatically boosted its holdings in Regeneron Pharmaceuticals by 56.3% during Q4, grabbing 1,361 shares worth nearly $969,000. Several other institutional investors also ...

April 9 (Reuters) - WW International (WW.O), opens new tab, also known as WeightWatchers, is preparing to file for bankruptcy in the coming months as part of a plan to hand control of the business ...

To permanently access this White Paper for free, fill out the short form below. Bispecific antibodies (bsAbs) represent a significant advancement in biologic therapeutics. However, their development ...

Atlas Capital Advisors didn’t just up their Regeneron stake—they launched it into orbit with a 5,620.3% increase, now holding $6 million in shares. Other institutional investors also shuffled their ...

The drug delivery approach of ABL is based on Grabody, a platform technology that develops bispecific antibodies, proteins engineered to bind to two targets. For treating brain diseases ...

A drugmaker with one of the world's top-selling drugs Regeneron (NASDAQ: REGN) is a well-established biotech company that generates consistent revenue and profits. However, the drugmaker ...

Merus stands out in biotech with its innovative Biclonics and Multiclonics platforms, focusing on bispecific and multispecific antibodies, particularly petosemtamab. Strong financials with $724 ...